This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Hyperion Therapeutics Announces First Quarter 2013 Operating Results

First Net Sales of RAVICTI Post-approval Reported at $0.8 Million Strong Cash Position of $102.7 million

SOUTH SAN FRANCISCO, Calif., May 9, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported the first commercial net sales of RAVICTIâ„¢ (glycerol phenylbutyrate) Oral Liquid as part of its financial operating results for the first quarter ended March 31, 2013.

Recent highlights:

  • RAVICTI received approval from the U.S. Food and Drug Administration (FDA) for treatment of Urea Cycle Disorders
  • Completed a follow-on public offering with net proceeds of $63.7 million
  • Received a key patent from the U.S. Patent Trademark Office for fasting ammonia that extends through 2032
  • Exercised the option to purchase both BUPHENYL® and AMMONUL®
  • Received Orphan Drug Exclusivity for RAVICTI from the FDA

"The February approval of our first product, RAVICTI, was a significant milestone for Hyperion Therapeutics and we are proud to bring this important new drug to the UCD community," said Donald J. Santel, president and chief executive officer of Hyperion Therapeutics, Inc. "We believe our launch one month earlier than anticipated reflects our commercial preparedness and our commitment to provide RAVICTI to patients. We were also able to effectively establish our specialty distribution model which provides important services not previously offered to the UCD community, including our patient assistance program. We've made good progress in providing Ravicti to patients thanks to effective communication with payers, and we are clearly off to an encouraging start. In April we exercised our option to acquire BUPHENYL and AMMONUL which provides us with added opportunities to diversify our portfolio and further serve the UCD community. Additionally, receiving patent approval and orphan exclusivity further enhances the value of Hyperion's UCD franchise."

First Quarter 2013 Financial Results

Hyperion reported a net loss of $9.0 million for the first quarter of 2013, or a net loss per share of $0.52, compared with a net loss of $11.9 million, or a net loss per share of $25.33 for the same period of 2012.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs